However, since LXR agonists are applied to the whole body, they may upregulate SREBP-1c expression and produce related undesired adverse reactions, including induction of adipogenesis, hypertriglyceridemia, and liver steatosis. This evidence concerns the gene SREBF1 and fatty liver disease.